Results 171 to 180 of about 111,053 (345)

Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care. Methods Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness!
Adrian Hunt   +9 more
wiley   +1 more source

Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis

open access: yesEuropean Journal of Clinical Investigation, EarlyView.
Central nervous system involvement in cardiac amyloidosis. Amyloidosis is a systemic disease that can directly affect the central nervous system. Furthermore, the amyloid cardiomyopathy can indirectly affect the central nervous system by inducing systemic hypoperfusion and increasing the risk of acute ischaemic stroke.
Domenico Mario Giamundo   +3 more
wiley   +1 more source

Start(up) with purpose: How goal‐ and duty‐based purpose drive work engagement and performance in startups

open access: yesEuropean Management Review, EarlyView.
ABSTRACT Although organizational purpose (OP) has recently gained attention in entrepreneurship research, its motivational potential in startups remains underexplored, limiting the development of effective purpose‐driven strategies to enhance employee work engagement (WE) and startup performance.
Julien A. Nussbaum   +3 more
wiley   +1 more source

Pharmacokinetics and adverse effects of a long‐acting IM dopamine agonist: Cabergoline in healthy horses

open access: yesEquine Veterinary Education, EarlyView.
Summary Background Pituitary pars intermedia dysfunction (PPID) is commonly treated with pergolide mesylate, a dopamine receptor agonist. Cabergoline is a dopamine receptor agonist that has shown activity on prolactin secretion in horses for up to 10 days.
H. Hess   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy